Skip to content
  • Home
  • News
  • Videos
  • Conference Coverage
  • Podcasts
  • Resource Centers
    • Acne
    • Skin Cancer
    • Alopecia
    • Atopic Dermatitis
    • Cosmetics
    • Hidradenitis Suppurativa (HS)
    • Pediatrics
    • Pigment Disorders
    • Practice Management
    • Psoriasis
    • Rare Diseases
    • Rosacea
    • Vitiligo
  • Home
  • News
  • Videos
  • Conference Coverage
  • Podcasts
  • Resource Centers
    • Acne
    • Skin Cancer
    • Alopecia
    • Atopic Dermatitis
    • Cosmetics
    • Hidradenitis Suppurativa (HS)
    • Pediatrics
    • Pigment Disorders
    • Practice Management
    • Psoriasis
    • Rare Diseases
    • Rosacea
    • Vitiligo
Subscribe

Long-acting EVO301 Shows Promise in Proof-of-concept AD Study

Evommune, Inc.’s EVO301 performed well in a Phase 2a proof-of-concept study in atopic dermatitis (AD), finds research presented at the 2026 European Academy of Dermatology and Venereology Congress in Vienna, Austria.

The Dermatology Digest is an independent, multi-channel resource for practicing dermatologists and dermatological practitioners.

Quick Links
  • Advertise with Us
  • About Us
  • Advertise with Us
  • About Us
Follow us
Linkedin Facebook-f X-twitter Youtube

© 2026 All Rights Reserved.